Aurinia (Formerly Known as Isotechnika Pharma Inc.)
5120 - 75th Street
287 articles about Aurinia (Formerly Known as Isotechnika Pharma Inc.)
Aurinia Completes Submission of New Drug Application to the U.S. Food & Drug Administration for Voclosporin for the Treatment of Lupus Nephritis
NDA Application supported by extensive global clinical program including the pivotal Phase 3 AURORA study and the pivotal Phase 2 AURA LV study
Aurinia Pharmaceuticals Inc. reported financial results for the first quarter ended March 31, 2020 and provided an update on recent operational highlights.
Aurinia Pharmaceuticals Inc. announced that it will release its first quarter 2020 financial results on Thursday, May 14, 2020, after the markets close.
Aurinia Pharmaceuticals Inc., a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, announced the appointment of Joe Miller as Chief Financial Officer.
Aurinia Pharmaceuticals Inc. announced the appointment of Timothy P. Walbert, chairman, president and chief executive officer of Horizon Therapeutics plc, to the Company’s Board of Directors.
Aurinia Announces AURORA Phase 3 Clinical Data for Voclosporin in Lupus Nephritis to be Presented at National Kidney Foundation 2020 Spring Clinical Meetings
Data to be shared as a late-breaking oral presentation during the live virtual NKF conference
Aurinia Pharmaceuticals Inc. announced that the Company has established its U.S. commercial center of operations in Rockville, Maryland.
Aurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the U.S. Food and Drug Administration for Voclosporin in the Treatment of Lupus Nephritis
Company remains on track to complete submission by the end of the second quarter 2020 -
Aurinia Launches Resource Kit for People Living With Lupus Nephritis and Partners With National Kidney Foundation on Awareness Initiative
Company recognizes World Kidney Day and National Kidney Month - Aurinia Pharmaceuticals Inc.
Cash and cash equivalents totaled approximately $306 million at December 31, 2019
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results on March 5, 2020
Aurinia Pharmaceuticals Inc. announced that it will release its fourth quarter and full year 2019 financial results on Thursday, March 5, 2020, after the markets close.
Aurinia Pharmaceuticals Inc. announced that Mr. Peter Greenleaf, President and Chief Executive Officer, will present a corporate overview at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2019 at 10:00 a.m. ET in New York, NY.
Aurinia Closes US$191.7 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares
The gross offering proceeds to the Company from this Offering are approximately US$191.7 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
Aurinia Pharmaceuticals Inc., a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, announced the pricing of its underwritten public offering of 11,115,165 common shares.
Aurinia Pharmaceuticals Inc., a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, announced that it has commenced a registered underwritten public offering of US$150,000,000 of its common shares.
12/9/2019It was, as usual, a pretty busy week in clinical trial news. Here’s a look.
Trial of Voclosporin Meets All Primary and Secondary Endpoints with Clean Safety Profile
Conference call and webcast to be hosted today at 4:30pm EDT
Aurinia Pharmaceuticals Inc. announced the appointment of Ms. Jill Leversage to its Board of Directors and the resignation of Dr. Hyeuk Joon Lee.
Aurinia Reports Last Patient Study Visit in Aurora Phase 3 Lupus Nephritis Study and Provides Update on ATM Facility
AURORA Phase 3 results with voclosporin for the treatment of lupus nephritis remain on track to be reported by the end of the fourth quarter 2019